Esté José A
Retrovirology Laboratory IrsiCaixa, Hospital Universitari Germans Trias i Pujol, Universitat Autónoma de Barcelona, Badalona, Spain.
Curr Opin Investig Drugs. 2002 Mar;3(3):379-83.
Schering-Plough is developing Sch-351125 (Sch-C), the lead in a series of CCR5 inhibitors, for the potential treatment of HIV infection. By March 2001, it had entered phase I studies in the US, however, by April 2001, these had been suspended based in part on observed QTc prolongation at the highest dose. By December 2001, a new phase I trial had been initiated in France. The company has continued to investigate a number of second-generation CCR5 receptor antagonists, including Sch-350634, for the potential treatment of HIV infection. Although it was reported at two separate meetings in early 2001 that Sch-350634 was in phase I/II trials, in April 2001, Schering-Plough confirmed that the compound was not in clinical development at that time and that a preclinical toxicology program was scheduled for late 2001. In December 2001, Morgan Stanley predicted a 2004 launch for a compound arising from the CCR5 inhibitor program, with sales of US$100 million in 2004, US$200 million in 2005, rising to US$300 million in 2006.
先灵葆雅公司正在研发CCR5抑制剂系列中的先导药物Sch-351125（Sch-C），用于潜在治疗HIV感染。到2001年3月，它已在美国进入I期研究，然而，到2001年4月，这些研究部分基于在最高剂量下观察到的QTc延长而暂停。到2001年12月，在法国启动了一项新的I期试验。该公司继续研究多种第二代CCR5受体拮抗剂，包括Sch-350634，用于潜在治疗HIV感染。尽管在2001年初的两次不同会议上报告称Sch-350634处于I/II期试验，但在2001年4月，先灵葆雅公司证实该化合物当时不在临床开发中，并且计划在2001年末开展临床前毒理学项目。2001年12月，摩根士丹利预测一种源自CCR5抑制剂项目的化合物将于2004年推出，2004年销售额为1亿美元，2005年为2亿美元，到2006年增至3亿美元。
